Cooper Companies sees flat to negative CooperVision growth in Q4 on inventory overhang

The Cooper Companies

09/09/2026 21:31

Overview
US medical device maker's fiscal Q3 revenue misses analyst expectations
Adjusted EPS for fiscal Q3 rose 4% and beat analyst expectations
Company repurchased $339.1 mln of stock and completed strategic review
Shares of the company were down about 14% in extended trading

Outlook
Cooper Companies sees Q4 revenue of $1.057-$1.080 bln, organic growth of 0%-2%, below Q3 pace 
Company expects Q4 non-GAAP diluted EPS of $1.05-$1.09
Cooper Companies reaffirms long-term free cash flow objective exceeding $2.2 bln for 2026-2028

Result Drivers
INVENTORY REDUCTION - CooperVision results were weighed down by a reduction in U.S. channel inventory, which the company said will continue to impact Q4
HIGHER COSTS AND FX - Non-GAAP gross margin declined due to higher manufacturing costs and unfavorable foreign exchange
FERTILITY SEGMENT GROWTH - CooperSurgical's fertility category saw solid growth, with organic revenue up 5% yr/yr

Company press release: ID:nGNX1BWK7H

Key Details
Metric
Beat/Miss
Actual
Consensus Estimate
Q3 Revenue
Miss
$1.07 bln
$1.10 bln (13 Analysts)
Q3 Adjusted EPS
Beat
$1.15
$1.12 (13 Analysts)
Q3 EPS
 
$2.24
 
Q3 Gross Margin
 
67.00%
 
Q3 Adjusted EBIT Margin
 
26.00%
 
Q3 EBIT Margin
 
21.00%
 

Analyst Coverage
The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 10 "strong buy" or "buy", 9 "hold" and no "sell" or "strong sell"
The average consensus recommendation for the medical equipment, supplies & distribution peer group is "buy"
Wall Street's median 12-month price target for The Cooper Companies, Inc. is $85.00, about 25.6% above its September 8 closing price of $67.69
The stock recently traded at 14 times the next 12-month earnings vs. a P/E of 13 three months ago

Reuters Recommended Reads
Sept 9 - Swiss medical device maker Medacta H1 revenue rises on Asia Pacific, EMEA strength
Sept 9 - Israel's Nano-X Imaging Q2 revenue misses estimates
Sept 8 - UK's Inspiration Healthcare H1 revenue falls on absence of prior-year export contracts

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)